0000899243-19-004460.txt : 20190221
0000899243-19-004460.hdr.sgml : 20190221
20190221194755
ACCESSION NUMBER: 0000899243-19-004460
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190219
FILED AS OF DATE: 20190221
DATE AS OF CHANGE: 20190221
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Francis Chris
CENTRAL INDEX KEY: 0001657709
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37627
FILM NUMBER: 19623710
MAIL ADDRESS:
STREET 1: C/O WAVE LIFE SCIENCES LTD.
STREET 2: 733 CONCORD AVE.
CITY: CAMBRIDGE
STATE: MA
ZIP: 02138
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Wave Life Sciences Ltd.
CENTRAL INDEX KEY: 0001631574
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: U0
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 7 STRAITS VIEW
STREET 2: #12-00, MARINA ONE EAST TOWER
CITY: SINGAPORE
STATE: U0
ZIP: 018936
BUSINESS PHONE: 617-949-2900
MAIL ADDRESS:
STREET 1: 733 CONCORD AVENUE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02138
FORMER COMPANY:
FORMER CONFORMED NAME: WAVE Life Sciences Ltd.
DATE OF NAME CHANGE: 20170516
FORMER COMPANY:
FORMER CONFORMED NAME: Wave Life Sciences Ltd.
DATE OF NAME CHANGE: 20151106
FORMER COMPANY:
FORMER CONFORMED NAME: Wave Life Sciences LTD.
DATE OF NAME CHANGE: 20151106
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-02-19
0
0001631574
Wave Life Sciences Ltd.
WVE
0001657709
Francis Chris
C/O WAVE LIFE SCIENCES LTD.,
733 CONCORD AVE.
CAMBRIDGE
MA
02138
0
1
0
0
See Remarks
Ordinary Shares
2019-02-19
4
S
0
1709
36.8397
D
20368
D
On February 19, 2019, the reporting person sold 1,709 ordinary shares solely to cover taxes associated with the vesting of restricted share units on February 15, 2019. These sales were made pursuant to a 10b5-1 Trading Plan.
The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $36.83 to $37.4713 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.1
SVP, Corporate Development, Head of Emerging Areas
/s/ Chris Francis
2019-02-21